Page 17 - hypertension_newsletter9

REFLECTIONS
Hypertension
Hypertension Global Newsletter #9 2025

12. Relationship between time in systolic target range during 24-hour ambulatory blood pressure monitoring and
mortality. Presenter: Lucas Lauder (University Hospital Basel, Switzerland). ESC Congress 2025. Hypertension

13. Underestimated versus accurate assessment of cardiovascular risk in hypertensive patients: A sub-analysis
of the SNAPSHOT study in Europe. Presenter: Arman Postadzhiyan (University Hospital St. Anne, Bulgaria). ESC
Congress 2025.
ECONOMICS AND PUBLIC HEALTH IMPACT

14. Cost-effectiveness of RF RDN in ESC Hypertension guideline-recommended indications in six European
countries: An analysis based on Global SYMPLICITY Registry DEFINE data. Presenter: Roland Schmieder (University
Hospital Erlangen, Germany). ESC Congress 2025.

15. What would be the impact on the burden of hypertension of achieving public health goals? Presenter: Clemence
Grave (Saint Maurice, France). ESC Congress 2025.

ESC 2025 – HOT LINE

16. BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled
or resistant hypertension. Williams B, Congress Presentation; (requires sign-in to access) Press release: https://
www.escardio.org/The-ESC/Press-Office/Press-releases/Blood-pressure-reductions-with-baxdrostat-in-patients-with-
uncontrolled-or-resistant-hypertension
17. Discussant review – BaxHTN. Guzik T, Congress Presentation; (requires sign-in to access)

18. Panel discussion – BaxHTN. Congress Presentation; (requires sign-in to access)

19. KARDIA-3: Zilebesiran as add-on therapy in adults with hypertension and established cardiovascular disease
or at high cardiovascular risk. Pagidipati N, Congress Presentation; (requires sign-in to access) Press release: https://
www.escardio.org/The-ESC/Press-Office/Press-releases/KARDIA-3-trial-examines-blood-pressure-lowering-effects-of-
zilebesiran-in-hypertensive-patients-at-high-cardiovascular-risk
20. Discussant review - KARDIA-3. Tomaszewski M, Congress Presentation; (requires sign-in to access)

21. Panel discussion - KARDIA-3. Congress Presentation; (requires sign-in to access)

Abbreviations

ACE, angiotensin-converting enzyme; AF, atrial fibrillation; AOSBP, automated office systolic blood pressure; ARB, angiotensin
receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; C, certainty;
CCB, calcium channel blocker; CI, certainty index; CI, confidence interval; CKD, chronic kidney disease; CLASS, classes of
recommendations; CPRD, clinical practice research datalink; CVD, cardiovascular disease; d, day; DASH, Dietary Approaches
to Stop Hypertension; DBP, diastolic blood pressure; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESC,
European Society of Cardiology; ESH, European Society of Hypertension; GL, guideline; HBPM, home blood pressure monitoring;
HES, hospital episode statistics; HF, heart failure; HR, hazard ratio; HTN, hypertension; LEVEL, levels of evidence; MD, mean
difference; MI, myocardial infarction; MRA, mineralocorticoid receptor agonist; NA, not applicable; ONS, office for national statistics;
PAT, pulse arrival time; PWA, pulse wave analysis; RAS, renin–angiotensin system; RCT, randomised clinical trial; SBP, systolic
blood pressure; SD, standard deviation; SPC, single-pill combination; TM, telemonitoring; TRH, treatment-resistant hypertension; UC,
uncertainty; wk, week.

TABLE OF CONTENTS